JP2009539994A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539994A5
JP2009539994A5 JP2009515473A JP2009515473A JP2009539994A5 JP 2009539994 A5 JP2009539994 A5 JP 2009539994A5 JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009539994 A5 JP2009539994 A5 JP 2009539994A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition
mammal
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013873 external-priority patent/WO2007146335A2/en
Publication of JP2009539994A publication Critical patent/JP2009539994A/ja
Publication of JP2009539994A5 publication Critical patent/JP2009539994A5/ja
Pending legal-status Critical Current

Links

JP2009515473A 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物 Pending JP2009539994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81283506P 2006-06-12 2006-06-12
PCT/US2007/013873 WO2007146335A2 (en) 2006-06-12 2007-06-12 Compounds and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013105196A Division JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物

Publications (2)

Publication Number Publication Date
JP2009539994A JP2009539994A (ja) 2009-11-19
JP2009539994A5 true JP2009539994A5 (enExample) 2010-07-29

Family

ID=38832517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009515473A Pending JP2009539994A (ja) 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Country Status (11)

Country Link
US (4) US8124773B2 (enExample)
EP (2) EP2043645A2 (enExample)
JP (3) JP2009539994A (enExample)
KR (1) KR20090021215A (enExample)
CN (2) CN104027333B (enExample)
AU (1) AU2007258280B2 (enExample)
BR (1) BRPI0713637A2 (enExample)
CA (1) CA2654876A1 (enExample)
IL (2) IL195883A0 (enExample)
MX (1) MX2008015775A (enExample)
WO (1) WO2007146335A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1729770T1 (sl) * 2004-03-15 2010-02-26 Sunesis Pharmaceuticals Inc SNS-595 in postopki za uporabo le-tega
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) * 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2214662B1 (en) 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2010078294A1 (en) * 2008-12-31 2010-07-08 Sunesis Pharmaceutical, Inc. Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2400959A1 (en) 2009-02-27 2012-01-04 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
AU2013202641B2 (en) * 2009-09-04 2015-07-23 Sunesis Pharmaceuticals, Inc. Stable sns-595 compositions and methods of preparation
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5078966A (en) 1990-08-14 1992-01-07 Nalco Chemical Company Carbohydrazide to prevent hydrogen blistering and corrosion of metal surfaces in contact with refinery overhead condensates
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
SI0787726T1 (en) * 1994-06-14 2002-04-30 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
US6753158B1 (en) 1997-01-13 2004-06-22 Kudos Pharmaceuticals Limited Assays, agents, therapy and diagnosis relating to modulation of cellular DNA repair activity
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
CA2293724C (en) * 1997-06-05 2010-02-02 Xiaodong Wang Apaf-1, the ced-4 human homolog, an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US6570002B1 (en) * 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2877202A (en) * 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US20030016887A1 (en) * 2001-07-18 2003-01-23 Fu-Long Su Receiving bag with seal opening and sealing clip
JP2006523681A (ja) 2003-03-24 2006-10-19 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン
SI1729770T1 (sl) 2004-03-15 2010-02-26 Sunesis Pharmaceuticals Inc SNS-595 in postopki za uporabo le-tega
US7387499B2 (en) 2004-08-13 2008-06-17 Gateway Inc. System and method for testing the operation of a cooling fan
EP1931339B1 (en) 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) * 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
WO2008016678A2 (en) 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
WO2008016702A2 (en) * 2006-08-02 2008-02-07 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
EP2214662B1 (en) 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders

Similar Documents

Publication Publication Date Title
JP2009539994A5 (enExample)
MX2009001130A (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
JP2009545600A5 (enExample)
JP2012067116A5 (enExample)
JP2014148535A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2009102342A5 (enExample)
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
JP2014040437A5 (enExample)
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
JP2011503063A5 (enExample)
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
RU2013121788A (ru) Ингибиторы репликации вич
EA201270383A1 (ru) Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2009013501A (es) Compuestos piperidinicos y sus usos.
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
JP2015527374A5 (enExample)
JP2008514577A5 (enExample)
JP2009517411A5 (enExample)
JP2010528091A5 (enExample)
MX2010004350A (es) Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
JP2014504636A5 (enExample)
RU2015101702A (ru) Фармацевтически активные соединения